Apr 7, 2025 12:25 pm EDT Adaptin Bio, Inc., a Lucius Partners Portfolio Company, Completes Alternative Public Offering (APO) and Closes $7.7 Million Private Placement
Sep 4, 2024 8:00 am EDT Adaptin Bio Announces FDA Clearance of IND Application for APTN-101 in Glioblastoma